NAD+ Research Overview (also known as Nicotinamide Adenine Dinucleotide, NMN)
A coenzyme found in every living cell and essential for ATP production, DNA repair, sirtuin activation, and mitochondrial function. NAD+ levels decline dramatically with age. Studied through precursor compounds (NMN and NR) and direct supplementation for longevity, cognitive function, and cellular resilience.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is NAD+?
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme present in every living cell and fundamental to hundreds of metabolic reactions. It serves dual roles: as an electron carrier in cellular respiration and as a substrate consumed by enzymes including sirtuins (longevity-associated deacylases), PARPs (DNA repair enzymes), and CD38 (a NAD+ hydrolase). The tension between these roles is central to aging biology.
NAD+ Decline with Aging
Cellular NAD+ levels decline by 40–60% between young adulthood and old age, driven by increased CD38 activity, accumulated DNA damage activating PARP enzymes, and reduced biosynthesis capacity. This decline impairs sirtuin activity, reduces mitochondrial biogenesis, compromises DNA repair fidelity, and accelerates the metabolic deterioration associated with aging.
Sirtuin Activation and Research
Sirtuins (SIRT1–7) are NAD+-dependent protein deacylases that regulate metabolism, stress resistance, genome stability, and aging at the epigenetic level. Restoring NAD+ levels through precursors (NMN, NR) or through NNMT inhibition reactivates these protective pathways. NAD+ repletion is studied for aging, cognitive decline, metabolic syndrome, hearing loss, kidney disease, and addiction recovery — reflecting NAD+'s ubiquitous role in cellular health.
Quick Reference
| Literature-Reported Dose Range | 25–100 mg daily, or 250–300 mg 2–3× weekly |
| Literature-Reported Frequency | Daily or 2–3× weekly |
| Literature-Reported Cycle Length | 8-12 weeks with evaluation |
| Literature-Reported Washout | 4-8 weeks between intensive cycles |
| Storage | Refrigerate 2-8°C, use within 28 days after reconstitution |
| Sites Reported in Studies | IM: deltoid, glute, thigh; SubQ: abdomen, thigh |
| Timing | Morning preferred for energy benefits |
Research Indications
Energy Metabolism
Cellular Energy Production
Restores mitochondrial function and ATP synthesis capacity
Metabolic Optimization
Enhances glucose and fat metabolism efficiency
Exercise Performance
Improves oxygen utilization and endurance capacity
Anti-Aging
DNA Repair Enhancement
Activates PARP enzymes for improved DNA repair mechanisms
Sirtuin Activation
Supports longevity pathways and cellular stress resistance
Senescence Reduction
May help clear senescent cells and improve tissue function
Neurological Support
Cognitive Enhancement
Improves mental clarity, focus, and memory formation
Neuroprotection
Supports neuronal health and reduces neuroinflammation
Neurotransmitter Support
Optimizes brain chemistry for mood and cognitive function
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General Wellness & Energy | 100-250mg | Daily or 2–3× weekly | SubQ or IM |
| Anti-Aging Protocol | 25–100 mg daily, or 250–300 mg 2–3× weekly | 2-3x weekly | SubQ |
| Cognitive Enhancement | 500-1000mg | Daily or 2–3× weekly | SubQ |
| Athletic Performance | 25–100 mg daily, or 250–300 mg 2–3× weekly | 2x weekly | SubQ or IM |
| Recovery & Repair | 500-1000mg | 3x weekly | SubQ |
| Maintenance Therapy | 100-250mg | 1x weekly | SubQ or IM |
Timing
Recommended administration window: morning preferred for energy benefits. Typical onset: 30 minutes to 2 hours for initial effects, cumulative benefits over weeks.
Peptide Interactions
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Combined protocols enhance cellular repair and energy production
Complementary effects on tissue regeneration and mitochondrial function
NAD+ supports metabolic pathways enhanced by GLP-1 agonists
Growth hormone pathways benefit from improved cellular energy metabolism
Enhanced recovery and anti-aging effects when combined
Alcohol consumption significantly reduces NAD+ levels and effectiveness
Both support mitochondrial function - NAD+ in electron transport chain, L-Carnitine in fatty acid transport for beta-oxidation
Reported Research Timeline
01Week 1–2 (reported in cited studies): initial energy improvements and mental clarity
02Week 3–4 (reported in cited studies): enhanced physical performance and recovery
03Week 5–8 (reported in cited studies): sustained energy levels and improved sleep quality
04Week 9–12 (reported in cited studies): optimized metabolic function and cognitive benefits
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Start with lower doses to assess tolerance
Administer SubQ or IM — avoid self-administering without guidance from a healthcare professional
Monitor for injection site reactions
Avoid alcohol consumption during treatment
Maintain consistent dosing schedule for best results
Seek Medical Attention If:
Severe injection site reactions or infection signs
Persistent nausea or gastrointestinal distress
Unusual fatigue or weakness after injections
Allergic reactions (rash, swelling, difficulty breathing)
Quality Indicators
Verified Marker
Clear, colorless solution
NAD+ solution should be transparent without particles
Verified Marker
Proper refrigeration
Stored consistently at 2-8°C for potency
Verified Marker
Sterile technique
Use proper sterile injection procedures
Acceptable Range
Reconstitution timing
Use within 28 days of mixing with bacteriostatic water
Quality Concern
Cloudy or discolored solution
May indicate contamination or degradation
Quality Concern
Room temperature storage
Heat degrades NAD+ rapidly, reducing effectiveness
Research Citations
- Intranasal NAD+ for Traumatic Brain Injury (2012)
Rats | 20 mg/kg intranasal | Post-TBI treatment | Hippocampal neuroprotection - Nicotinamide Riboside Safety & Metabolism Study (2019)
Human | 100-1000mg oral daily | 8 weeks | Well-tolerated, increased NAD+ - Age-Associated NAD+ Decline in Human Tissue (2012)
Human tissue analysis | Multiple organs studied | Cross-sectional | 10-50% decline with age - Nicotinamide Riboside Bioavailability in Humans (2016)
Human | 100-1000mg oral | Single dose pharmacokinetics | Dose-dependent NAD+ elevation - NMN Efficacy in Middle-Aged Adults (2022)
Human | 300-900mg oral daily | 60 days | Multicenter RCT - CD38-Targeting Peptide Vaccine Ameliorates Aging-Associated Phenotypes in Mice
Yu S, Li Z, Tang Y, 2025, Aging Cell - From Pharmacophore to Warhead: NAD(+)-Targeting Triazoles as Mechanism-Based Sirtuin Inhibitors
Friedrich F, Meleshin M, Papenkordt N, 2025, Angew Chem Int Ed Engl - Mono-ADP-Ribosylation Catalyzed by Arginine-Specific ADP-Ribosyltransferases
Stevens LA, Moss J, 2018, Methods Mol Biol - NAD-dependent ADP-ribosylation of the human antimicrobial and immune-modulatory peptide LL-37 by ADP-ribosyltransferase-1
Picchianti M, Russo C, Castagnini M, 2015, Innate Immun - NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons
Wu MF, Yin JH, Hwang CS, 2014, Free Radic Res
Research Focus
Cellular energy, DNA repair, Sirtuin activation, Anti-aging, Mitochondrial function, Longevity
Verified Vendors Carrying NAD+
Frequently Asked Questions
What should researchers watch for with NAD+?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with NAD+?
Week 1–2 (reported in cited studies): initial energy improvements and mental clarity
How is NAD+ typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →